You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR LIRAGLUTIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Liraglutide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00154401 ↗ Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 2005-01-01 This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
NCT00154414 ↗ Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 2 2005-01-01 This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.
NCT00294723 ↗ To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c Terminated Novo Nordisk A/S Phase 3 2006-02-01 This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).
NCT00318422 ↗ Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2006-05-01 This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride.
NCT00318461 ↗ To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together Completed Novo Nordisk A/S Phase 3 2006-05-01 This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of metformin monotherapy and combination therapy of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised, double-blinded period followed by an 18 months open-label extension, in total 2 years (104 weeks).
NCT00331851 ↗ Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2006-05-01 This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.
NCT00333151 ↗ Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 3 2006-05-01 This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Liraglutide

Condition Name

Condition Name for Liraglutide
Intervention Trials
Diabetes Mellitus, Type 2 109
Diabetes 109
Obesity 85
Type 2 Diabetes 45
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Liraglutide
Intervention Trials
Diabetes Mellitus 229
Diabetes Mellitus, Type 2 205
Diabetes Mellitus, Type 1 36
Obesity 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Liraglutide

Trials by Country

Trials by Country for Liraglutide
Location Trials
Canada 142
India 133
China 118
South Africa 63
Denmark 60
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Liraglutide
Location Trials
California 66
Texas 61
Florida 59
New York 57
Ohio 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Liraglutide

Clinical Trial Phase

Clinical Trial Phase for Liraglutide
Clinical Trial Phase Trials
Phase 4 114
Phase 3 106
Phase 2/Phase 3 9
[disabled in preview] 173
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Liraglutide
Clinical Trial Phase Trials
Completed 271
Recruiting 50
Unknown status 37
[disabled in preview] 64
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Liraglutide

Sponsor Name

Sponsor Name for Liraglutide
Sponsor Trials
Novo Nordisk A/S 181
Eli Lilly and Company 10
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 9
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Liraglutide
Sponsor Trials
Other 388
Industry 243
NIH 18
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.